Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Research And Development Expense of $607.16 million for the year ending 2025.
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +20.0% in Research And Development Expense from 2024 to 2025.
- This data is from ARROWHEAD PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on November 25, 2025.
- XBRL data for this metric is available from 2011 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $123.3 thousand | Q4 2010: $2.26 million | Q1 2011: $140.7 thousand | Q2 2011: $365.6 thousand | Q4 2011: $769.1 thousand | Q1 2012: $1.36 million | Q2 2012: $1.22 million | Q4 2012: $1.58 million | Q1 2013: $2.13 million | Q2 2013: $1.76 million | Q4 2013: $3.13 million | Q1 2014: $5.22 million | Q2 2014: $6.39 million | Q4 2014: $17.74 million | Q1 2015: $11.64 million | Q2 2015: $7.49 million | Q4 2024: $137.00 million | Q4 2025: $177.20 million.
- Over the full 8 years of available data (2011 to 2025), ARROWHEAD PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 18,423.6%.
- Historical annual values: Fiscal year 2025: $607.16 million | Fiscal year 2024: $505.87 million | Fiscal year 2023: $353.19 million | Fiscal year 2015: $47.27 million | Fiscal year 2014: $23.14 million | Fiscal year 2013: $8.71 million | Fiscal year 2012: $5.39 million | Fiscal year 2011: $3.28 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: